-
公开(公告)号：US20160160294A1
公开(公告)日：2016-06-09
申请号：US14962588
申请日：2015-12-08
Applicant: Tesaro , Myriad Genetics, Inc.
Inventor： Keith Wilcoxen , Alexander Gutin , Kirsten Timms , Victor Abkevich , Yan Wang , Jerry Lanchbury
IPC: C12Q1/68 , A61K31/454
CPC classification number: C12Q1/6886 , A61K31/454 , C12Q2600/106 , C12Q2600/158
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature to predict response to niraparib. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature to predict response to niraparib are provided.
Abstract translation: 本文件提供了评估样品（例如癌细胞）是否存在同源重组缺陷（HRD）或HRD特征以预测对尼拉帕布反应的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否含有HRD特征以预测对尼拉帕布的反应的方法和材料。
-
公开(公告)号：US20160145681A1
公开(公告)日：2016-05-26
申请号：US15010721
申请日：2016-01-29
Applicant: Myriad Genetics, Inc.
Inventor： Alexander Gutin , Kirsten Timms , Jerry Lanchbury
IPC: C12Q1/68
CPC classification number: C12Q1/6827 , C12Q1/6858 , C12Q1/6874 , C12Q1/6883 , G06F19/22 , C12Q2535/122 , C12Q2537/143
Abstract: Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.
Abstract translation: 提供了使用核酸测序检测等位基因不平衡的方法和系统。
-
43.发明申请公开(公告)号：US20140363521A1
公开(公告)日：2014-12-11
申请号：US14245576
申请日：2014-04-04
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Kirsten Timms , Alexander Gutin
CPC classification number: C12Q1/6886 , A61K33/24 , C12Q1/6827 , C12Q1/6858 , C12Q2600/106 , C12Q2600/154 , C12Q2600/156 , G16B20/00 , C12Q2535/122 , C12Q2537/143
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Abstract translation: 本文件提供了评估样品（例如癌细胞）中存在同源重组缺陷（HRD）或HRD标记的方法和材料。 例如，提供了用于确定细胞（例如，癌细胞）是否包含HRD特征的方法和材料。 还提供了用于鉴别具有同源性定向修复（HDR）缺陷的细胞（例如癌细胞）的材料和方法以及用于鉴定可能对特定癌症治疗方案作出反应的癌症患者的材料和方法。
-
公开(公告)号：US12221656B2
公开(公告)日：2025-02-11
申请号：US18081603
申请日：2022-12-14
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Kirsten Timms , Alexander Gutin , Julia Reid
IPC: C12Q1/6886
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：US12180551B2
公开(公告)日：2024-12-31
申请号：US17966689
申请日：2022-10-14
Applicant: Myriad Genetics, Inc.
Inventor： Alexander Gutin , Julia Reid , Ralf Kronenwett , Marsel Scheer
Abstract: Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.
-
Patent Agency Ranking
公开(公告)号：US20220259675A1
公开(公告)日：2022-08-18
申请号：US17678357
申请日：2022-02-23
Applicant: MYRIAD GENETICS, INC.
Inventor： Steven Stone , Alexander Gutin , Susanne Wagner , Julia E. Reid
IPC: C12Q1/6886
Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
-
公开(公告)号：US20220112565A1
公开(公告)日：2022-04-14
申请号：US17484179
申请日：2021-09-24
Applicant: Myriad Genetics, Inc.
Inventor： Steven Stone , Alexander Gutin , Julia Reid
IPC: C12Q1/6886
Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
-
公开(公告)号：US20210071269A1
公开(公告)日：2021-03-11
申请号：US17096755
申请日：2020-11-12
Applicant: MYRIAD GENETICS, INC.
Inventor： Steven Stone , Alexander Gutin , Susanne Wagner , Julia Reid
IPC: C12Q1/6886
Abstract: Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.
-
公开(公告)号：US20190185939A1
公开(公告)日：2019-06-20
申请号：US16221165
申请日：2018-12-14
Applicant: Myriad Genetics, Inc.
Inventor： Victor Abkevich , Kirsten Timms , Alexander Gutin , Julia Reid
IPC: C12Q1/6886
CPC classification number: C12Q1/6886 , C12Q2600/106 , C12Q2600/156
Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
-
公开(公告)号：US20190032144A1
公开(公告)日：2019-01-31
申请号：US16026839
申请日：2018-07-03
Applicant: Myriad Genetics, Inc.
Inventor： Darl Flake , Alexander Gutin , Douglas Adams
IPC: C12Q1/6886
Abstract: Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
-
-
-
-
-
-
-
-
-
Search Results
68
records
(took 0.029 seconds)
